NPY and breast cancer: The study also assessed the targeting of 99mTc-BRL with two breast cancer cell lines xenografts: estrogen receptor-positive (MCF-7, expressing both NPY and αVβ3 receptors) and triple-negative (MDA-MB231, expressing high in αVβ3 and low in NPY).